Skip to main content
. 2023 Jan 10;88:104430. doi: 10.1016/j.ebiom.2022.104430

Fig. 1.

Fig. 1

(a) Experimental schema for the study; (b) Anti-SARS-CoV-2 spike RBD antibody concentrations in patients receiving ChAdOx1 nCoV-19 (black dots) or BNT162b2 (pink squares). Each point represents a single patient plotted the number of days after second dose of vaccine when their antibody level was measured.